Assessment Status | Rapid review complete |
HTA ID | 21044 |
Drug | Zanubrutinib |
Brand | Brukinsa® |
Indication | Monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy |
Assessment Process | |
Rapid review commissioned | 11/10/2021 |
Rapid review completed | 16/11/2021 |
Rapid review outcome | A full HTA is not recommended. The NCPE recommends that zanubrutinib (Brukinsa®) not be considered for reimbursement at the submitted price* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013